Score Your Stock

US stock · figures in US dollars · scored on full-year results

Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc.

REGN · Healthcare · Biotechnology
Top 50% of scored stocks
OkayTop 50% of scored stocks
Weak SpotOne-off Dividend

Regeneron Pharmaceuticals scores 54/100 on fundamentals: in the top 50% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (100/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, One-off Dividend.

Best
Financial 100
Weakest
Price 0
  • Carries a Weak Spot flag
  • Carries a One-off Dividend flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 95.5b#125 of 503 in the S&P 500EPSUS$ 40.44P/E22.1×✓ vs sector median 30.5×P/B3×✓ vs sector median 4×Div yield0%Bottom 26% in the S&P 50052w range · 98% of range591.52935.35
as of 31 Oct 2026

Nearby peers

Ranks #30 of 60 in Healthcare by score

#1Universal Health Services79#28Bio-Techne55#29HCA Healthcare54
#30Regeneron Pharmaceuticals54
#31Revvity54#32Biogen53

One-Minute Summary

Why Regeneron Pharmaceuticals scores 54

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

60
Why 60?
Pillar score: (1 + 1 + 1 + 2 + 1) = 6 of 10 points → 60
Return on Equity (ROE)14%Okay4-Year Revenue Growth+6%/yrOkay4-Year Profit Growth+3%/yrOkayNet Profit Margin28%StrongQuarterly Momentum+9%Okay
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +9.5%Equity ↑ +22.1%ROE % 13.7%
Net ProfitEquityROE %
4.0b4.4b4.5b4.3b26.0b29.4b31.3b31.7b202320242025TTM15.2%15%14.4%13.7%

Revenue & Net Profit, with Net Margin

Revenue ↑ +18.4%Net Profit ↑ +9.5%Net Margin % 27.9%
RevenueNet ProfitNet Margin %
13.1b14.2b14.3b15.5b4.0b4.4b4.5b4.3b202320242025TTM30.1%31.1%31.4%27.9%

Sales grew about 18.4% over 4 years: customers keep spending more with this company.

Profit has moved sideways: stable, but not compounding your money faster each year.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +15.3%Net Profit ↓ -3.3%Net Margin % 30.2%
RevenueNet ProfitNet Margin %
3.7b3.8b3.0b3.7b3.8b3.9b3.6b4.3b1.3b918m809m1.4b1.5b845m727m1.3bQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2636%24.2%26.7%37.9%38.9%21.7%20.2%30.2%
▲▼▲▬▲▼▼▼

Sales grew about 15.3% over the last 8 quarters: customers keep spending more with this company.

Profit has moved sideways over the last 8 quarters.

Why 100?
Pillar score: (2 + 2 + 2) = 6 of 6 points → 100
Debt-to-Equity0.1×StrongCurrent Ratio3.3×StrongInterest Coverage94.3×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt → +0.1%Equity ↑ +22.1%D/E 0.1×
Total DebtEquityD/E
2.7b2.7b2.7b2.7b26.0b29.4b31.3b31.7b202320242025TTM0.1×0.1×0.1×0.1×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↓ -5.3%Current Liabilities ↑ +61.6%Current Ratio 3.3×
Current AssetsCurrent LiabilitiesCurrent Ratio
19.5b18.7b18.0b18.4b3.4b3.9b4.4b5.5b202320242025TTM5.7×4.7×4.1×3.3×
Why 50?
Pillar score: (0 + 1 + 2 + 1) = 4 of 8 points → 50
Dividend Quality0%Weak
Payout ratio: 9%
Operating Cash FlowPositive but bumpyOkayFree Cash FlowPositive & growingStrongCash & Cash EquivalentsPartly healthyOkay
Show 3 charts

Operating vs Free Cash Flow

Operating CF → +1.9%Free CF → -2.5%
Operating CFFree CF
4.6b4.4b5.0b4.7b3.7b3.5b3.8b3.6b202320242025TTM

Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.

Cash vs Total Debt

Cash ↓ -10%Total Debt → +0.1%
CashTotal Debt
2.7b2.5b3.1b2.5b2.7b2.7b2.7b2.7b202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0.4%
DPS (cents)Yield %
88888800035220222023202420250%0%0%0.4%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio22.1×WeakP/B Ratio3×WeakPEG Ratio7.2Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 927.89US$ 768.56US$ 609.23Oct '25Feb '26Jun '26Oct '26

The share price is up about 43.1% over the past year.

Why 58?
Pillar score: (2 + 1 + 2 + 1 + 1 + 0) = 7 of 12 points → 58
Earnings ConsistencySteadyStrongDebt Trend (4yr)StableOkayShare Count Trend (4yr)-2%/yrStrongInventory vs Sales (4yr)+0.3 pp/yr vs salesOkayAsset Turnover Trend (4yr)-6.1%OkayQuarterly Consistency3 of 4 quarters downWeak
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +18.4%Inventory ↑ +19.5%Inv. % of Rev. 19.9%
RevenueInventoryInv. % of Rev.
13.1b14.2b14.3b15.5b2.6b3.1b3.2b3.1b202320242025TTM19.7%21.7%22.3%19.9%
Ranks #30 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#28Bio-Techne55#29HCA Healthcare54
#30Regeneron Pharmaceuticals (you)54
#31Revvity54#32Biogen53

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 15.5bUS$ 4.3bUS$ 4.7bUS$ 3.6bUS$ -1.1bUS$ 2.5bUS$ 2.7bUS$ 720.0mUS$ 31.7bUS$ 18.4bUS$ 5.5bUS$ 41.7bUS$ 10.0bUS$ 3.1b-14%28%0.1×3.3×94.3×9%----
2025US$ 14.3bUS$ 4.5bUS$ 5.0bUS$ 3.8bUS$ -1.2bUS$ 3.1bUS$ 2.7b-US$ 31.3bUS$ 18.0bUS$ 4.4bUS$ 40.6bUS$ 9.3bUS$ 3.2bUS$ 352.0m14%31%0.1×4.1×120.4×8%0%18.2×2.6×14.4
2024US$ 14.2bUS$ 4.4bUS$ 4.4bUS$ 3.5bUS$ -881.6mUS$ 2.5bUS$ 2.7b-US$ 29.4bUS$ 18.7bUS$ 3.9bUS$ 37.8bUS$ 8.4bUS$ 3.1bUS$ 0.0m15%31%0.1×4.7×87.6×0%0%17.7×2.7×20.8
2023US$ 13.1bUS$ 4.0bUS$ 4.6bUS$ 3.7bUS$ -926.4mUS$ 2.7bUS$ 2.7b-US$ 26.0bUS$ 19.5bUS$ 3.4bUS$ 33.1bUS$ 7.1bUS$ 2.6bUS$ 0.0m15%30%0.1×5.7×58.5×0%0%24.1×3.7×-